首页> 外国专利> Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and type 2 diabetes.

机译：口服制剂模拟Roux-en-Y胃旁路对回肠制动的作用;用于治疗代谢综合症表现的成分，治疗方法，诊断和系统，包括胰岛素抵抗，脂肪肝，高脂血症和2型糖尿病。

页面导航

摘要
著录项
相似文献

摘要

The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome.;In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.

机译：本发明提供了药物组合物，用于治疗各种代谢综合征的药物组合物，方法以及与之相关的诊断和计算机可执行系统，所述代谢综合征包括高脂血症，体重增加，肥胖症，胰岛素抵抗，高血压，动脉粥样硬化，脂肪肝疾病和某些慢性炎症状态。在本发明的另一个方面，将组合物和治疗方法校准为对手术干预例如回肠的回声制动反应。 Roux-en-Y胃旁路手术（RYGB）均可激活回肠制动，回肠制动作用于哺乳动物的胃肠道和肝脏，以控制代谢综合征的表现，从而逆转或减轻心血管损害（动脉粥样硬化，高血压，脂质堆积）等）。净收益是可以用一种药物治疗代谢综合征的所有常见表现形式，包括2型糖尿病和肥胖症，该药物含有葡萄糖作为回肠制动的激活剂。回肠制动是代谢综合征进展的控制者，RYGB手术和口服制剂均通过该途径对代谢综合征表现出有益作用。还公开了协同作用于回肠制动和代谢综合征表现的组合药物。在其他方面，本发明提供了回肠制动激素释放组合物，治疗方法，诊断方法和用于选择性控制食欲的相关系统，稳定血糖和胰岛素水平，并以与RYGB手术相似的方式治疗胃肠道疾病，但具有至少20％的潜力来刺激人类回肠制动的激素反应。

著录项

公开/公告号US2017014436A1

专利类型
公开/公告日2017-01-19

原文格式PDF
申请/专利权人 VOLANT HOLDINGS GMBH;
展开▼

申请/专利号US201615151358
发明设计人 JOSEPH M. FAYAD;JEROME SCHENTAG;
展开▼

申请日2016-05-10
分类号A61K31/7004;A61K45/06;A61K31/155;A61K31/40;A61K9/28;A61K9;A61K36/48;A61K36/05;A61K31/555;A61K36/8998;A61K9/48;A61K31/4985;
国家 US
入库时间 2022-08-21 13:49:40

相似文献

专利
外文文献